Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study

Tommaso Bucci,Paul Rj Ames,Vittoria Cammisotto,Simona Bartimoccia,Massimo Triggiani,Roberta Parente,Antonio Ciampa,Pasquale Pignatelli,Roberto Carnevale,Daniele Pastori

Journal of Autoimmunity（2022）

引用 2|浏览9

暂无评分

摘要

•PCSK9 is an important risk factor for cardiovascular events.•High plasma PCSK9 levels are associated with arterial and recurrent thrombosis in patients with thrombotic PAPS.•PCSK9 should be considered as a contributing factor to thrombotic risk in PAPS.•PCSK9 inhibition may represent a secondary prevention strategy in PAPS at high thrombotic risk.

查看译文

关键词

Antiphospholipid syndrome,PCSK9,Thrombosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要